Form 4: Omeros Director Thomas Bumol Receives Annual Stock Option Grant

Omeros Corporation's Director, Thomas F. Bumol, was granted 15,000 stock options with an exercise price of $3.20 per share as part of the company's non-employee director compensation policy.

Summary

• Thomas F. Bumol, a Director of Omeros Corporation (OMER), was granted 15,000 stock options on June 27, 2025.
• The stock options have an exercise price of $3.20 per share.
• This grant was an automatic annual award pursuant to Omeros Corporation's non-employee director compensation policy, coinciding with the annual meeting of shareholders.
• The options will fully vest and become exercisable on the day before the 2026 annual meeting of Omeros Corporation shareholders, provided Mr. Bumol continues to serve as a director through that date.
• The expiration date for these stock options is June 27, 2035.

Sentiment

Score: 7

Explanation: The document reports a routine, pre-scheduled compensation event for a director, which is generally viewed as a neutral to slightly positive governance practice as it aligns director incentives with shareholder interests. It does not indicate specific operational performance or financial health beyond the existence of a compensation policy.

Positives

• The grant of stock options aligns the director's financial interests with long-term shareholder value, incentivizing performance that benefits the company's stock price.
• The award is part of a pre-defined, automatic non-employee director compensation policy, indicating a structured and transparent approach to governance.

Risks

• The value of the granted stock options is contingent on Omeros Corporation's common stock price increasing above the $3.20 exercise price.
• The options' vesting is conditional on the director's continued service, meaning they could be forfeited if service ceases before the vesting date.

Future Outlook

The granted stock options are set to fully vest and become exercisable on the day before the 2026 annual meeting of Omeros Corporation shareholders, provided the director maintains continuous service until that date.

Management Comments

• The stock option award was granted pursuant to Omeros Corporation's non-employee director compensation policy, which automatically grants options to eligible non-employee directors on the date of each annual meeting of shareholders.

Industry Context

Equity compensation, such as stock option grants to non-employee directors, is a common practice across the biotechnology and pharmaceutical industries. This strategy aims to align the interests of board members with those of shareholders, fostering long-term value creation and director retention.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a standard compensation mechanism widely adopted by publicly traded companies, including those in the biotechnology sector, to incentivize long-term commitment and performance.
• The specific volume of options (15,000) and the exercise price ($3.20) are determined by Omeros Corporation's established compensation policy and current market conditions. A detailed comparison would require analyzing director compensation packages of peer companies within the biotechnology industry of similar market capitalization and stage of development to assess competitiveness and alignment with industry benchmarks.

Related Party Transactions

• Grant of 15,000 stock options to Thomas F. Bumol, a non-employee director, as part of the company's standard compensation policy for directors.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's financial interests with long-term shareholder value, potentially encouraging decisions that enhance the company's stock price.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• Thomas F. Bumol's continued service as a director through the day before the 2026 annual meeting for the stock options to fully vest.
• Potential exercise of the vested stock options by Thomas F. Bumol at or after the vesting date, subject to the company's stock price performance.

Key Dates

Keywords

Omeros Corporation, OMER, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Thomas F. Bumol